Related Experiment Video
Updated: Jun 6, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function
João Silva1, Rui Pinto, Tiago Carvalho
1Department of Urology, Hospital S. João, Institute for Molecular and Cell Biology, Porto, Portugal.
BJU International
|November 26, 2010
Summary
Intraprostatic botulinum toxin type A injections for benign prostatic hyperplasia do not negatively impact male sexual function or hormone levels. This treatment offers a safe option for lower urinary tract symptoms refractory to standard therapies.
Area of Science:
- Urology
- Andrology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) affects a significant portion of aging men.
- Intraprostatic injection of botulinum toxin type A (BoNT/A) is an emerging treatment for BPH.
- Potential impact of BoNT/A on male sexual function requires thorough investigation.
Purpose of the Study:
- To assess the effects of intraprostatic BoNT/A on male sexual function in BPH patients.
- To evaluate changes in erectile function, orgasmic/ejaculatory function, and libido.
- To determine the impact of BoNT/A on key male hormonal markers.
Main Methods:
- 16 sexually active men >60 years with BPH/BPE received 200 U of intraprostatic BoNT/A.
- Sexual function assessed using the International Index of Erectile Function (IIEF) questionnaires.
- Hormonal profiles (testosterone, LH, FSH, prolactin) were monitored pre- and post-treatment.
Main Results:
- No significant changes were observed in erectile function (IIEF-5 scores) at 1, 3, and 6 months post-injection.
- Orgasmic/ejaculatory function and libido scores remained stable throughout the study period.
- Serum levels of total testosterone, LH, FSH, and prolactin showed no significant alterations.
Conclusions:
- Intraprostatic BoNT/A injections for BPH/BPE do not impair erectile, orgasmic, or ejaculatory functions.
- Libido and male hormonal profiles remain unaffected by this treatment.
- BoNT/A presents a viable therapeutic option for lower urinary tract symptoms in BPH patients unresponsive to conventional treatments.
Related Concept Videos
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:17Male Sexual Response: Erection & Ejaculation
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...